Clinical Trials Browser

OTHER × trilaciclib × Clear all

NCT06992739 2026-04-14

PROTECT-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

Phase 2 Recruiting

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07255612 2025-12-01

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06955156 2025-05-02

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06752798 2024-12-31

CCRT，LA-HNSCC

Phase 2 Recruiting

Head and Neck Neoplasms

NCT06714266 2024-12-03

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06714383 2024-12-03

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Phase 2 Recruiting

Osteosarcoma

NCT06698965 2024-11-21

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06699472 2024-11-21

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Phase 2 Recruiting

Sarcoma, Ewing

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Phase 2 Recruiting

Myelosuppression

NCT06569459 2024-08-26

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Phase 2 Unknown

NSCLC

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT06217003 2024-01-22

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Phase 2 Unknown

Osteosarcoma

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

Breast Neoplasms

NCT05862610 2023-07-24

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Phase 2 Unknown

Advanced Squamous Non-Small-Cell Lung Cancer